Efficacy Of Two Drugs On The Persistent HR-HPV Infection Of Cervix

Objective: To compare the efficacy of anti-HPV biological protein dressing and recombinant human interferon ?-2b gel on the treatment of high risk human papillomavirus(HR-HPV)persistent infection in cervix.Methods: A total of 80 patients diagnosed cervical persistent HR-HPV infection from October 2014 to February 2016 were randomly divided into group A(anti-HPV biological protein dressing group)and group B(recombinant human interferon ?-2b gel group),with 40 patients in each group.High-risk HPV-DNA typing was reexamined at 3 months,6 months and 9 months respectively after treatment and colposcopy was reexamined if HR-HPV infection was still present.Patients with abnormal results of liquid-based cytology and colposcopy and pathological examination were reexamined at 9months after therapy.The negative conversion rate of HR-HPV infection,changes of detective results of liquid-based cytology and colposcopy and pathological examination,the adverse drug reactions in the two groups were compared.Results: 1.In patients with persistent HR-HPV infection,76.25% were 31-50 years of age.2.The main types of persistent infection with single HR-HPV were type 16,58 and 52(P<0.005).The main mixed infection type was type 52 combined with other types(P<0.05).3.The negative conversion rate of persistent HR-HPV infection in group A was 30.00%,50.00% and 60.00% respectively at the 3rd,6th and 9th month after treatment,and 10.00%,25% and 37.5% in group B respectively.The comparison of negative conversion rate of persistent HR-HPV infection in two groups at the same time point was significantly different(P<0.05)and both were higher in the ninth month than that in the third month after therpy(P<0.05).4.There was no significant difference in the results of liquid-based cytology and colposcopy before and after treatment in both groups(P>0.05).5.There was no serious adverse drug reaction in the two groups.Conclusion: The efficacy of anti-HPV biological protein dressing is better than that of the recombinant human interferon ?-2b gel on persistent HR-HPV infection of cervix.